Abstract:Abstract Background MicroRNAs (miRNAs) represent a class of ∼22nt short non‐coding RNAs that have been identified as a sophisticated layer of post‐transcriptional regulation, governing many cellular, inflammatory and vascular processes. Their biological importance, together with the observation that miRNAs are frequently secreted into the extracellular space and stable in blood serum/plasma and other body fluids, make them specific, robust and non‐invasive biomarkers that could augment the amyloid and tau framework. miRNAs have been used for the detection of prodromal and early Alzheimer’s disease (AD) (e.g., mild cognitive impairment (MCI) due to AD) and to improve the differential diagnosis of AD. However, to date no miRNA panel has been translated into a clinical test. Method In collaboration with the University of Göttingen, the University of Erlangen and Zentralinstitut für Seelische Gesundheit in Mannheim, we prospectively collected PAXgene whole blood from 225 individuals (55‐85 years of age, MMSE ≥20) phenotyped at the respective memory clinics according to state‐of‐the‐art AD diagnostics including CSF core biomarkers. Amyloid positivity as a well validated proxy of brain β‐amyloidosis was determined using a CSF ABeta 42 /ABeta 40 threshold of 0.075. Thus, 127 individuals were ABeta(+) and 96 individuals were ABeta(‐). We deployed 100‐fold cross validation of a linear regression classifier to construct and validate small RNA feature models to evaluate their utility as biomarkers for amyloid positivity and AD diagnosis. Result We generated small RNA feature models and report a median diagnostic receiver operating area under the curve (AUC) of 0.66 (95% CI 0.59‐0.76) for amyloid positivity (ABeta 42 /ABeta 40 < 0.075). We deconvolved our whole blood sRNA signature into their respective plasma or immune cell origin. We found that the predicting features largely originate from the plasma fraction of whole blood (48.8%), marking a significant increase over the unselected distribution of all features (13.1%) of 3.72‐fold (p<0.001). However, several predictive features were found to originate from peripheral immune cells, particularly of the lymphoid arm (CD4+, CD8+ and B‐cells). Conclusion These data suggest the potential of a small RNA‐based blood test as a viable complement to the AT(N) framework for the management of individuals at risk for AD.

Peripheral Blood MicroRNA Expression Profiles in Alzheimer’s Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.

Genome-wide Analysis of Mirna Signature in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease.

Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer’s Disease

MicroRNA-4722-5p and microRNA-615-3p serve as potential biomarkers for Alzheimer's disease

Early Detection of Alzheimer’s Disease using microRNAs

miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study

MicroRNA-135a and -200B, Potential Biomarkers for Alzheimer׳s Disease, Regulate Β Secretase and Amyloid Precursor Protein.

Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review

MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy

Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease

Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers

Identification of miRNA-Target Gene Pairs in the Parietal and Frontal Lobes of the Brain in Patients with Alzheimer’s Disease Using Bioinformatic Analyses

Genome-Wide Serum Microrna Expression Profiling Identifies Serum Biomarkers for Alzheimer'S Disease

Immune abnormalities and differential gene expression in the hippocampus and peripheral blood of patients with Alzheimer’s disease

Serum MicroRNA Profiles Serve As Novel Biomarkers for the Diagnosis of Alzheimer’s Disease

Whole Transcriptome Sequencing of Peripheral Blood Identifies the Alzheimer's Disease-Related circRNA-miRNA-lncRNA Pathway

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

Whole-Blood Levels of MicroRNA-9 Are Decreased in Patients With Late-Onset Alzheimer Disease